Skip to main content
All lobbying filings

RK Strategies, Inc.

RK Strategies, Inc. filed a Q2 report for Recce Pharmaceuticals Ltd. on July 18, 2026, reporting $20,000 in lobbying income.

Lobbying for Recce Pharmaceuticals Ltd. · Pharmaceutical Company - Anti-infectives

As filed: RK STRATEGIES, INC. for RECCE PHARMACEUTICALS LTD.

All filings by RK Strategies, Inc. · Everything Recce Pharmaceuticals Ltd. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 18, 2026
Income
$20,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

General healthcare/wound care issues Pandemic and All Hazards Preparedness Act Reauthorization Appropriations Issues

General biodefense/wound care issues Pandemic and All Hazards Preparedness Act Reauthorization Other Appropriations Issues Related to Wound Care/Biodefense

General wound care issues

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem